<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649476</url>
  </required_header>
  <id_info>
    <org_study_id>HStomatologyWuhan</org_study_id>
    <nct_id>NCT04649476</nct_id>
  </id_info>
  <brief_title>Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma</brief_title>
  <acronym>NEOPBOSCC</acronym>
  <official_title>A Randomized Phase II Study of Neoadjuvant PD-1 Blockade Alone or Plus TPF Induction Chemotherapy for Resectable Local Advanced Oral Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital of Stomatology, Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital of Stomatology, Wuhan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and feasibility of neoadjuvant PD-1&#xD;
      blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy in subjects with&#xD;
      resectable local advanced oral squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic response.</measure>
    <time_frame>8 weeks.</time_frame>
    <description>Pathologic response of resected tumors and lymph nodes to neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy. The rate of major pathologic response, defined as &lt;10% residual viable tumor cells in the resected specimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic response.</measure>
    <time_frame>8 weeks.</time_frame>
    <description>Clinical response of tumors and lymph nodes to neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy, as evaluated by radiographic examinations and defined by RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) rate on each treatment arm.</measure>
    <time_frame>24 months.</time_frame>
    <description>EFS is the time from the date of randomization to the date of first record of disease progression as defined by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) on each treatment arm.</measure>
    <time_frame>24 months.</time_frame>
    <description>OS is the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs).</measure>
    <time_frame>24 months.</time_frame>
    <description>Number of participants experiencing any sign, symptom, disease, or worsening of preexisting conditions temporally associated with the experimental interventions or irrespective of the experimental interventions.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in the level of circualting exosomal PD-L1.</measure>
    <time_frame>24 months.</time_frame>
    <description>The level of circulating exosomal PD-L1 at serial time points pre- and on-treatment, as detected by enzyme-linked immunosorbent assay (ELISA).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Oral Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant PD-1 blockade alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive 3 doses of neoadjuvant PD-1 blockade. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant PD-1 blockade plus TPF induction chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive 3 doses of PD-1 blockade and 2 courses of TPF induction chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>The participants will receive camrelizumab (200 mg) intravenous infusion each 2-week cycle for 3 cycles prior to surgery.</description>
    <arm_group_label>Neoadjuvant PD-1 blockade alone</arm_group_label>
    <other_name>SHR-1210</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumanb plus TPF</intervention_name>
    <description>The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.</description>
    <arm_group_label>Neoadjuvant PD-1 blockade plus TPF induction chemotherapy</arm_group_label>
    <other_name>Docetaxel, Cisplatin, 5-Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically documented oral squamous cell carcinoma (biopsy required).&#xD;
&#xD;
          2. Local advanced oral squamous cell carcinoma (clinical stage T1-2N1-3M0, T3-4aN0-3M0)&#xD;
             with resection option for potential cure, as assessed by a faculty surgeon at Hospital&#xD;
             of Stomatology, Wuhan University.&#xD;
&#xD;
          3. Distant metastasis is excluded by chest CT and emission computed tomograph.&#xD;
&#xD;
          4. Adequate organ function as follows: 1) Leukocyte count ≥ 2,000/mm3; 2) Absolute&#xD;
             neutrophil count ≥ 1,000/mm3; 3) Platelet count ≥ 100,000/mm3; 4) Hemoglobin ≥ 90 g/L;&#xD;
             5) Serum albumin ≥30 g/L; 6) Total bilirubin ≤ 1.5 × upper limit of normal (ULN); 7)&#xD;
             AST (SGOT) and ALT (SGPT) &lt; 2.5 × ULN; 8) ALP ≤ 2.5 × ULN; 9) Prothrombin&#xD;
             time-international normalized ratio ≤ 1.5; 10) Serum creatinine ≤ 1.5 × ULN; 11)&#xD;
             INR/PT≤ 1.5; 12) TSH ≤ ULN.&#xD;
&#xD;
          5. ECOG performance status 0-1.&#xD;
&#xD;
          6. Female patient tested HCG negative in serum or urine within 7 days prior to the start&#xD;
             of investigational product. Both patient and partner must agree to use contraception&#xD;
             prior to study entry and for the duration of study participation and for up to 120&#xD;
             days after the last dose of PD-1 blockade.&#xD;
&#xD;
          7. Patient understands the study regimen, its requirements, risks and discomforts and is&#xD;
             able and willing to sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of ≥ 3 grade immune related adverse events (irAEs) or have not recovered to ≤&#xD;
             1 grade irAEs from previous treatment.&#xD;
&#xD;
          2. History of other treatments for cancer, including surgery, chemotherapy, radiotherapy&#xD;
             or molecular targeted therapy within past 5 years.&#xD;
&#xD;
          3. Previous therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 or any other&#xD;
             antibody targeting T cell co-regulatory pathways.&#xD;
&#xD;
          4. Active autoimmune disease or history of refractory autoimmune disease.&#xD;
&#xD;
          5. Active systemic infection requiring therapy.&#xD;
&#xD;
          6. Patients who are receiving psychotropic drug or alcohol/drug abuse.&#xD;
&#xD;
          7. Subjects with concurrent other active malignancies.&#xD;
&#xD;
          8. HIV or untreated active HBV or HCV infections, or vaccinated (HBV, flu, varicella,&#xD;
             etc) within 4 weeks before recruitment.&#xD;
&#xD;
          9. Uncontrollable systemic diseases, including diabetes, hypertension, etc.&#xD;
&#xD;
         10. History of stroke or transient ischemic attack within past 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of Stomatology, Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Chen, M.D.</last_name>
    <phone>+86 02787686215</phone>
    <email>geraldchan@whu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of Stomatology, Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Gang Chen, M.D.</last_name>
      <phone>+86 02787686215</phone>
      <email>geraldchan@whu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital of Stomatology, Wuhan University</investigator_affiliation>
    <investigator_full_name>Gang Chen</investigator_full_name>
    <investigator_title>Chief physician, Professor</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>Oral squamous cell carcinoma</keyword>
  <keyword>PD-1 blockade</keyword>
  <keyword>Camrelizumab</keyword>
  <keyword>TPF induction chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

